These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 25441685)

  • 1. Effect of telomerase inhibition on preclinical models of malignant rhabdoid tumor.
    Hu Y; Bobb D; Lu Y; He J; Dome JS
    Cancer Genet; 2014 Sep; 207(9):403-11. PubMed ID: 25441685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The HSP90 inhibitor alvespimycin enhances the potency of telomerase inhibition by imetelstat in human osteosarcoma.
    Hu Y; Bobb D; He J; Hill DA; Dome JS
    Cancer Biol Ther; 2015; 16(6):949-57. PubMed ID: 25920748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Telomerase inhibitor imetelstat has preclinical activity across the spectrum of non-small cell lung cancer oncogenotypes in a telomere length dependent manner.
    Frink RE; Peyton M; Schiller JH; Gazdar AF; Shay JW; Minna JD
    Oncotarget; 2016 May; 7(22):31639-51. PubMed ID: 27192120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Telomerase antagonist imetelstat inhibits esophageal cancer cell growth and increases radiation-induced DNA breaks.
    Wu X; Smavadati S; Nordfjäll K; Karlsson K; Qvarnström F; Simonsson M; Bergqvist M; Gryaznov S; Ekman S; Paulsson-Karlsson Y
    Biochim Biophys Acta; 2012 Dec; 1823(12):2130-5. PubMed ID: 22906540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The telomerase inhibitor imetelstat alone, and in combination with trastuzumab, decreases the cancer stem cell population and self-renewal of HER2+ breast cancer cells.
    Koziel JE; Herbert BS
    Breast Cancer Res Treat; 2015 Feb; 149(3):607-18. PubMed ID: 25627551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The telomerase inhibitor imetelstat depletes cancer stem cells in breast and pancreatic cancer cell lines.
    Joseph I; Tressler R; Bassett E; Harley C; Buseman CM; Pattamatta P; Wright WE; Shay JW; Go NF
    Cancer Res; 2010 Nov; 70(22):9494-504. PubMed ID: 21062983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The telomerase antagonist, imetelstat, efficiently targets glioblastoma tumor-initiating cells leading to decreased proliferation and tumor growth.
    Marian CO; Cho SK; McEllin BM; Maher EA; Hatanpaa KJ; Madden CJ; Mickey BE; Wright WE; Shay JW; Bachoo RM
    Clin Cancer Res; 2010 Jan; 16(1):154-63. PubMed ID: 20048334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Telomerase antagonist imetelstat increases radiation sensitivity in esophageal squamous cell carcinoma.
    Wu X; Zhang J; Yang S; Kuang Z; Tan G; Yang G; Wei Q; Guo Z
    Oncotarget; 2017 Feb; 8(8):13600-13619. PubMed ID: 28099140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BIBR1532, a Selective Telomerase Inhibitor, Enhances Radiosensitivity of Non-Small Cell Lung Cancer Through Increasing Telomere Dysfunction and ATM/CHK1 Inhibition.
    Ding X; Cheng J; Pang Q; Wei X; Zhang X; Wang P; Yuan Z; Qian D
    Int J Radiat Oncol Biol Phys; 2019 Nov; 105(4):861-874. PubMed ID: 31419512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imetelstat (a telomerase antagonist) exerts off‑target effects on the cytoskeleton.
    Mender I; Senturk S; Ozgunes N; Akcali KC; Kletsas D; Gryaznov S; Can A; Shay JW; Dikmen ZG
    Int J Oncol; 2013 May; 42(5):1709-15. PubMed ID: 23545855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Telomerase inhibition abolishes the tumorigenicity of pediatric ependymoma tumor-initiating cells.
    Barszczyk M; Buczkowicz P; Castelo-Branco P; Mack SC; Ramaswamy V; Mangerel J; Agnihotri S; Remke M; Golbourn B; Pajovic S; Elizabeth C; Yu M; Luu B; Morrison A; Adamski J; Nethery-Brokx K; Li XN; Van Meter T; Dirks PB; Rutka JT; Taylor MD; Tabori U; Hawkins C
    Acta Neuropathol; 2014 Dec; 128(6):863-77. PubMed ID: 25120190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized phase II study of the telomerase inhibitor imetelstat as maintenance therapy for advanced non-small-cell lung cancer.
    Chiappori AA; Kolevska T; Spigel DR; Hager S; Rarick M; Gadgeel S; Blais N; Von Pawel J; Hart L; Reck M; Bassett E; Burington B; Schiller JH
    Ann Oncol; 2015 Feb; 26(2):354-62. PubMed ID: 25467017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MDM2 and MDM4 Are Therapeutic Vulnerabilities in Malignant Rhabdoid Tumors.
    Howard TP; Arnoff TE; Song MR; Giacomelli AO; Wang X; Hong AL; Dharia NV; Wang S; Vazquez F; Pham MT; Morgan AM; Wachter F; Bird GH; Kugener G; Oberlick EM; Rees MG; Tiv HL; Hwang JH; Walsh KH; Cook A; Krill-Burger JM; Tsherniak A; Gokhale PC; Park PJ; Stegmaier K; Walensky LD; Hahn WC; Roberts CWM
    Cancer Res; 2019 May; 79(9):2404-2414. PubMed ID: 30755442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Telomerase antagonists GRN163 and GRN163L inhibit tumor growth and increase chemosensitivity of human hepatoma.
    Djojosubroto MW; Chin AC; Go N; Schaetzlein S; Manns MP; Gryaznov S; Harley CB; Rudolph KL
    Hepatology; 2005 Nov; 42(5):1127-36. PubMed ID: 16114043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Telomerase inhibitor Imetelstat (GRN163L) limits the lifespan of human pancreatic cancer cells.
    Burchett KM; Yan Y; Ouellette MM
    PLoS One; 2014; 9(1):e85155. PubMed ID: 24409321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imetelstat, a telomerase inhibitor, differentially affects normal and malignant megakaryopoiesis.
    Mosoyan G; Kraus T; Ye F; Eng K; Crispino JD; Hoffman R; Iancu-Rubin C
    Leukemia; 2017 Nov; 31(11):2458-2467. PubMed ID: 28270692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A molecular biology and phase II study of imetelstat (GRN163L) in children with recurrent or refractory central nervous system malignancies: a pediatric brain tumor consortium study.
    Salloum R; Hummel TR; Kumar SS; Dorris K; Li S; Lin T; Daryani VM; Stewart CF; Miles L; Poussaint TY; Stevenson C; Goldman S; Dhall G; Packer R; Fisher P; Pollack IF; Fouladi M; Boyett J; Drissi R
    J Neurooncol; 2016 Sep; 129(3):443-451. PubMed ID: 27350411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Telomerase inhibitors: a patent review (2010-2015).
    Man RJ; Chen LW; Zhu HL
    Expert Opin Ther Pat; 2016 Jun; 26(6):679-88. PubMed ID: 27104627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathology and diagnosis of SMARCB1-deficient tumors.
    Margol AS; Judkins AR
    Cancer Genet; 2014 Sep; 207(9):358-64. PubMed ID: 25246033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of IGFBP7 expression and persistent AKT activation contribute to SMARCB1/Snf5-mediated tumorigenesis.
    Darr J; Klochendler A; Isaac S; Eden A
    Oncogene; 2014 Jun; 33(23):3024-32. PubMed ID: 23851500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.